These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36355216)

  • 1. Identifying participants' preferences for modifiable chemotherapy-induced peripheral neuropathy prevention clinical trial factors: an adaptive choice-based conjoint analysis.
    Knoerl R; Berry D; Meyerhardt JA; Reyes K; Salehi E; Thornton K; Gewandter JS
    Support Care Cancer; 2022 Dec; 30(12):9963-9973. PubMed ID: 36355216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical assessment of chemotherapy-induced peripheral neuropathy: a discrete choice experiment of patient preferences.
    Yu A; Street D; Viney R; Goodall S; Pearce A; Haywood P; Haas M; Battaglini E; Goldstein D; Timmins H; Park SB
    Support Care Cancer; 2021 Nov; 29(11):6379-6387. PubMed ID: 33884508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis.
    Kuriyama A; Endo K
    Support Care Cancer; 2018 Apr; 26(4):1051-1059. PubMed ID: 29280005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN).
    Schloss JM; Colosimo M; Airey C; Masci P; Linnane AW; Vitetta L
    Support Care Cancer; 2017 Jan; 25(1):195-204. PubMed ID: 27612466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring Chemotherapy-Induced Peripheral Neuropathy Management Practice Patterns Among Oncology Clinicians.
    Kanzawa-Lee G; Krauss JC; Knoerl R
    Semin Oncol Nurs; 2024 Oct; 40(5):151685. PubMed ID: 38937199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the efficacy of an electronic symptom assessment and self-care intervention to preserve physical function in individuals receiving neurotoxic chemotherapy.
    Knoerl R; Weller E; Halpenny B; Berry D
    BMC Cancer; 2018 Dec; 18(1):1203. PubMed ID: 30514351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying trajectories and predictors of chemotherapy-induced peripheral neuropathy symptoms, physical functioning, and falls across treatment and recovery in adults treated with neurotoxic chemotherapy: the PATTERN observational study protocol (NCT05790538).
    Winters-Stone KM; Krasnow SM; Horak FB; Mancini M; Cameron MH; Dieckmann NF; Stoyles SA; Roeland EJ
    BMC Cancer; 2023 Nov; 23(1):1087. PubMed ID: 37946117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling.
    Kolb NA; Smith AG; Singleton JR; Beck SL; Stoddard GJ; Brown S; Mooney K
    JAMA Neurol; 2016 Jul; 73(7):860-6. PubMed ID: 27183099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention, diagnosis and management of chemotherapy-induced peripheral neuropathy: a cross-sectional study of French oncologists' professional practices.
    Selvy M; Pereira B; Kerckhove N; Busserolles J; Farsi F; Guastella V; Merle P; Pezet D; Balayssac D
    Support Care Cancer; 2021 Jul; 29(7):4033-4043. PubMed ID: 33403401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Self-Reported Severity, Characteristics, and Functional Limitations of Chemotherapy-Induced Peripheral Neuropathy.
    Knoerl R; Mazzola E; Hong F; Salehi E; McCleary N; Ligibel J; Reyes K; Berry DL
    Pain Manag Nurs; 2022 Aug; 23(4):532-540. PubMed ID: 34972658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evaluation of changes in peripheral neuropathy and quality-of-life using low-frequency electrostimulation in patients treated with chemotherapy for breast cancer: a study protocol.
    Jang CE; Jung MS; Sohn EH; Kim M; Yoo HS; Bae K; Kim JR; Lee JS
    Trials; 2018 Sep; 19(1):526. PubMed ID: 30268158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy-Induced Peripheral Neuropathy Detection via a Smartphone App: Cross-sectional Pilot Study.
    Chen CS; Kim J; Garg N; Guntupalli H; Jagsi R; Griggs JJ; Sabel M; Dorsch MP; Callaghan BC; Hertz DL
    JMIR Mhealth Uhealth; 2021 Jul; 9(7):e27502. PubMed ID: 36260403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring Patients' Understanding of Chemotherapy-Induced Peripheral Neuropathy.
    Knoerl R; Berry DL; Meyerhardt J; Reyes K; Salehi E; Gewandter JS
    J Cancer Educ; 2023 Jun; 38(3):906-912. PubMed ID: 35927535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the impact of a decision support algorithm to improve clinicians' chemotherapy-induced peripheral neuropathy assessment and management practices: a two-phase, longitudinal study.
    Knoerl R; Mazzola E; Hong F; Salehi E; McCleary N; Ligibel J; Reyes K; Berry DL
    BMC Cancer; 2021 Mar; 21(1):236. PubMed ID: 33676431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the reliability and validity of clinically-relevant outcome measures for chemotherapy-induced peripheral neuropathy.
    Knoerl R; Sohn MB; Spath K; Burnette B; Francar L; Mustian KM; Shah D; Gauthier L; Gewandter JS
    Support Care Cancer; 2024 Sep; 32(10):675. PubMed ID: 39297964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation by Ozone Therapy of Oxidative Stress in Chemotherapy-Induced Peripheral Neuropathy: The Background for a Randomized Clinical Trial.
    Clavo B; Martínez-Sánchez G; Rodríguez-Esparragón F; Rodríguez-Abreu D; Galván S; Aguiar-Bujanda D; Díaz-Garrido JA; Cañas S; Torres-Mata LB; Fabelo H; Téllez T; Santana-Rodríguez N; Fernández-Pérez L; Marrero-Callico G
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN).
    Hertz DL; Childs DS; Park SB; Faithfull S; Ke Y; Ali NT; McGlown SM; Chan A; Grech LB; Loprinzi CL; Ruddy KJ; Lustberg M
    Cancer Treat Rev; 2021 Sep; 99():102241. PubMed ID: 34174668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes.
    Li T; Timmins HC; Trinh T; Mizrahi D; Harrison M; Horvath LG; Grimison P; Friedlander M; Kiernan MC; King MT; Rutherford C; Goldstein D; Park SB
    J Natl Compr Canc Netw; 2023 Feb; 21(2):125-132.e3. PubMed ID: 36791763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Redefining chemotherapy-induced peripheral neuropathy through symptom cluster analysis and patient-reported outcome data over time.
    Wang M; Cheng HL; Lopez V; Sundar R; Yorke J; Molassiotis A
    BMC Cancer; 2019 Nov; 19(1):1151. PubMed ID: 31775665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy-induced peripheral neuropathy (CIPN) and its treatment: an NIH Collaboratory study of claims data.
    Gewandter JS; Kleckner AS; Marshall JH; Brown JS; Curtis LH; Bautista J; Dworkin RH; Kleckner IR; Kolb N; Mohile SG; Mustian KM
    Support Care Cancer; 2020 Jun; 28(6):2553-2562. PubMed ID: 31494735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.